Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
26
0
1

Year Published

1997
1997
2018
2018

Publication Types

Select...
7
2
1

Relationship

0
10

Authors

Journals

citations
Cited by 47 publications
(28 citation statements)
references
References 16 publications
1
26
0
1
Order By: Relevance
“…2c) may result from both displacement of an endogenous-bound agonist complemented by direct suppression of transactivation by bound antagonist ligand. This view may further indicate the means for treating selected MODY-1 subjects by excess HNF-4␣ agonist ligands or by selective drugs designed to restore transcriptional activity by protein-ligand complementation (42,43).…”
Section: Resultsmentioning
confidence: 99%
“…2c) may result from both displacement of an endogenous-bound agonist complemented by direct suppression of transactivation by bound antagonist ligand. This view may further indicate the means for treating selected MODY-1 subjects by excess HNF-4␣ agonist ligands or by selective drugs designed to restore transcriptional activity by protein-ligand complementation (42,43).…”
Section: Resultsmentioning
confidence: 99%
“…TRIAC has a higher affinity for these receptors than T 3 yet the role of local conversion is probably more important and may partly explain the relative lower potency of TRIAC for TSH inhibition than T 4 (15). It cannot explain, however, the difference with T 3 .…”
Section: Discussionmentioning
confidence: 95%
“…Among the TH analogues used to alleviate symptoms of apparent TH excess [127], triiodothyroacetic acid (TRIAC) has had the widest use [128,129]. The combination of greater affinity for TRIAC than T 3 of some mut TRβs [130] and its short half-life, produce greater effect centrally than on peripheral tissues. This reduces TSH and TH secretion with apparent amelioration of hypermetabolism.…”
Section: Rthmentioning
confidence: 99%